Novo Nordisk to test key hemophilia drug in children in phase III

In a phase III trial, Novo Nordisk will investigate whether Mim8, which stems from a collaboration with Genmab, has potential to treat children with hemophilia A.

Photo: Tidsvilde Stine/Ritzau Scanpix

Pharmaceutical firm Novo Nordisk will not focus its attention exclusively on adults and adolescents when the pivotal testing phase of hemophilia drug Mim8 begins later this year.

According to database Clinical Trials, which collects information about ongoing and future drug testing, Novo Nordisk is also preparing for a phase III trial comparing Mim8, which is based on Genmab’s Duobody technology platform, to other medicines in children with hemophilia A.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs